drugset / Trial / NCT02968394
Omalizumab Treatment in Venom Immunotherapy With Systemic Reactions
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate if omalizumab co-treatment may allow reintroduction of honey bee venom immunotherapy in patients with immunotherapy treatment failure due to systemic reactions.
Timeline
- Start
- 2014-03
- Primary completion
- 2017-03
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omalizumab | Monoclonal antibody | — | — |